• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Overlays

Quote
Anonymous said:
I agree that the overlay concept is awkward with our accounts and uncomfortable in our daily routine, but I also agree that expansion is going to happen with bg12. You have a choice: support the overlay you have now who will have a year under their belt or take the new hire of next year with 3-6 months at best. I have no idea what my overlay makes, but he works hard and I'm not getting paid any less. I am taking the high road, supporting and being nice to my overlay b/c I'll take him over the unknown big pharma rep.
Click to expand...
You guys are so lucky. You get to sell BG12....that drug is a winner. I bet those biogen reps who left for Novartis are regretting it now.
 




With the latest bg-12 data, Chuck will have to expand - like it or not. Avonex will be second string and Tysabri will be tied to Elan. I wouldn't mind a smaller footprint.
 








Expansion....Are you serious???? My accounts are already laughing at us for tripping over each other now.....We have become the Pfizer of biotech...Soon Chuck will order us to have POD meetings.....WTF????? I don't care how good the BG-12 data is, this IS NOT a reach and frequency market you dumb ass.....
 




























As of now, it looks like 90 Tysabri leads, 90 Avonex leads, 90 BG12 leads. So we are going to expand by 45, hired and trained to hit field by July 1st. Most territories will have 3 reps mirroring each doctor.

And it looks like the current Avonex reps will have BG12 as their secondary product. Yup, you heard me right! Chuck is handing our new product to a group of new reps!!!!
 




Gotta love Biogen marketing for BG12 mimicking old big pharma days. Mirrors, counterparts, overlays....etc. What's next, quad pods, roomates at meetings, and a max bonus of 6k per quarter? Too bad, once a great company, but when upper management makes decisions like this it's got to make you wonder.
 




Anonymous said:
As of now, it looks like 90 Tysabri leads, 90 Avonex leads, 90 BG12 leads. So we are going to expand by 45, hired and trained to hit field by July 1st. Most territories will have 3 reps mirroring each doctor.

And it looks like the current Avonex reps will have BG12 as their secondary product. Yup, you heard me right! Chuck is handing our new product to a group of new reps!!!!
Click to expand...

He does that and you can hire another 25 new Avonex leads on top of the 45 expansion reps. Avonex leads have been selling a mature drug over a dozen years old and paying dues by keeping the cash cow afloat waiting for that something new (BG12) to discuss when customers ask.
If they give BG 12 primary to the expansion reps...count the reps that head for the door.
 
























Anonymous said:
Gotta love Biogen marketing for BG12 mimicking old big pharma days. Mirrors, counterparts, overlays....etc. What's next, quad pods, roomates at meetings, and a max bonus of 6k per quarter? Too bad, once a great company, but when upper management makes decisions like this it's got to make you wonder.
Click to expand...

hate to admit it, this is where biotech is heading following big pharma
 








Top Bottom
Back
Quote